| scholarly article | Q13442814 |
| P50 | author | Vilmundur Gudnason | Q28050060 |
| Gudny Eiriksdottir | Q29840793 | ||
| Thor Aspelund | Q30112513 | ||
| Pablo Moscato | Q48588595 | ||
| Cristina Legido-Quigley | Q52448581 | ||
| Kristaps Klavins | Q63385217 | ||
| Lenore J Launer | Q66739234 | ||
| Madhav Thambisetty | Q71775824 | ||
| P2093 | author name string | Palmi V Jonsson | |
| Sudhir Varma | |||
| Yang An | |||
| Min Kim | |||
| Ramon Casanova | |||
| Santiago Saldana | |||
| Michael Griswold | |||
| Carlos Riveros | |||
| Denise Sonntag | |||
| Judith Wahrheit | |||
| Brittany Simpson | |||
| P2860 | cites work | Metabolomics in early Alzheimer's disease: identification of altered plasma sphingolipidome using shotgun lipidomics | Q21560953 |
| Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease | Q24595802 | ||
| Recent advances in the application of metabolomics to Alzheimer's Disease | Q26828606 | ||
| The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease | Q29547554 | ||
| The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease | Q29614406 | ||
| Targeted metabolomics identifies reliable and stable metabolites in human serum and plasma samples | Q31152141 | ||
| Identification of a new plasma biomarker of Alzheimer's disease using metabolomics technology | Q33452881 | ||
| Blood-based biomarkers of Alzheimer's disease: challenging but feasible | Q33824444 | ||
| Differences between human plasma and serum metabolite profiles | Q33961437 | ||
| Evaluation of a previously suggested plasma biomarker panel to identify Alzheimer's disease | Q34141675 | ||
| Cerebral microbleeds, retinopathy, and dementia: the AGES-Reykjavik Study | Q34455591 | ||
| Identification of altered metabolic pathways in plasma and CSF in mild cognitive impairment and Alzheimer's disease using metabolomics. | Q34735142 | ||
| Metabolome in progression to Alzheimer's disease | Q35844155 | ||
| Sphingomyelin SM(d18:1/18:0) is significantly enhanced in cerebrospinal fluid samples dichotomized by pathological amyloid-β42, tau, and phospho-tau-181 levels | Q36424510 | ||
| Translating biomarkers to clinical practice | Q37119173 | ||
| The Baltimore Longitudinal Study of Aging (BLSA): a 50-year-long journey and plans for the future | Q37216751 | ||
| Age, Gene/Environment Susceptibility-Reykjavik Study: multidisciplinary applied phenomics | Q37297554 | ||
| Plasma phospholipids identify antecedent memory impairment in older adults. | Q37714213 | ||
| Design and analysis of metabolomics studies in epidemiologic research: a primer on -omic technologies | Q38223336 | ||
| Toward metabolomic signatures of cardiovascular disease | Q42554863 | ||
| Quantitative and Wide-Ranging Profiling of Phospholipids in Human Plasma by Two-dimensional Liquid Chromatography/Mass Spectrometry | Q42827068 | ||
| Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins | Q44917427 | ||
| Age-specific incidence rates of Alzheimer's disease: the Baltimore Longitudinal Study of Aging. | Q51976760 | ||
| Evidence of altered phosphatidylcholine metabolism in Alzheimer's disease. | Q54996405 | ||
| A proposed metabolic strategy for monitoring disease progression in Alzheimer's disease | Q57972006 | ||
| P433 | issue | 7 | |
| P921 | main subject | Alzheimer's disease | Q11081 |
| P304 | page(s) | 815-822 | |
| P577 | publication date | 2016-01-21 | |
| P1433 | published in | Alzheimer's and Dementia | Q15750965 |
| P1476 | title | Blood metabolite markers of preclinical Alzheimer's disease in two longitudinally followed cohorts of older individuals | |
| P478 | volume | 12 |
| Q52609763 | A Blood Test for Alzheimer's Disease: Progress, Challenges, and Recommendations. |
| Q51760901 | A Decade of Blood Biomarkers for Alzheimer's Disease Research: An Evolving Field, Improving Study Designs, and the Challenge of Replication. |
| Q91944526 | A Review on MS-Based Blood Biomarkers for Alzheimer's Disease |
| Q64093631 | A metabolomic approach to identifying biomarkers in blood of Alzheimer's disease |
| Q47201004 | Alpha-2 macroglobulin in Alzheimer's disease: a marker of neuronal injury through the RCAN1 pathway. |
| Q58586046 | Alzheimer's Biomarkers From Multiple Modalities Selectively Discriminate Clinical Status: Relative Importance of Salivary Metabolomics Panels, Genetic, Lifestyle, Cognitive, Functional Health and Demographic Risk Markers |
| Q40444820 | Association between Plasma Ceramides and Phosphatidylcholines and Hippocampal Brain Volume in Late Onset Alzheimer's Disease |
| Q51764769 | Association of branched-chain amino acids and other circulating metabolites with risk of incident dementia and Alzheimer's disease: A prospective study in eight cohorts. |
| Q92898110 | Biomarkers in Alzheimer's, Frontotemporal, Lewy Body, and Vascular Dementias |
| Q38980003 | Blood Biomarkers for Alzheimer's Disease: Much Promise, Cautious Progress |
| Q89762134 | Blood Metabolite Signature of Metabolic Syndrome Implicates Alterations in Amino Acid Metabolism: Findings from the Baltimore Longitudinal Study of Aging (BLSA) and the Tsuruoka Metabolomics Cohort Study (TMCS) |
| Q89804524 | Blood Metabolite Signatures of Metabolic Syndrome in Two Cross-Cultural Older Adult Cohorts |
| Q99710861 | Blood biomarkers indicate that the preclinical stages of Alzheimer's disease present overlapping molecular features |
| Q49135523 | Blood-based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic |
| Q64108130 | Blood-based molecular biomarkers for Alzheimer's disease |
| Q95579827 | Blood-based systems biology biomarkers for next-generation clinical trials in Alzheimer's disease |
| Q47423721 | Body mass index and risk of dementia: Analysis of individual-level data from 1.3 million individuals |
| Q47549112 | Brain and blood metabolite signatures of pathology and progression in Alzheimer disease: A targeted metabolomics study. |
| Q61447841 | Can targeted metabolomics predict depression recovery? Results from the CO-MED trial |
| Q47587631 | Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry |
| Q39386254 | Characterizing Alzheimer's disease through metabolomics and investigating anti-Alzheimer's disease effects of natural products |
| Q64084604 | Cognitive Profiling Related to Cerebral Amyloid Beta Burden Using Machine Learning Approaches |
| Q38603323 | Cognitive and imaging markers in non-demented subjects attending a memory clinic: study design and baseline findings of the MEMENTO cohort |
| Q101564177 | Concordant peripheral lipidome signatures in two large clinical studies of Alzheimer's disease |
| Q64120423 | Cytokines and Chemokines in Pediatric Appendicitis: A Multiplex Analysis of Inflammatory Protein Mediators |
| Q38778638 | Defeating Alzheimer's disease and other dementias: a priority for European science and society |
| Q42323524 | Early Effect of Amyloid β-Peptide on Hippocampal and Serum Metabolism in Rats Studied by an Integrated Method of NMR-Based Metabolomics and ANOVA-Simultaneous Component Analysis. |
| Q58723601 | High-Throughput Direct Mass Spectrometry-Based Metabolomics to Characterize Metabolite Fingerprints Associated with Alzheimer's Disease Pathogenesis |
| Q104111087 | Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies |
| Q91843441 | Isobaric mass tagging and triple quadrupole mass spectrometry to determine lipid biomarker candidates for Alzheimer's disease |
| Q42655692 | Lower brain and blood nutrient status in Alzheimer's disease: Results from meta-analyses |
| Q91758950 | Machine Learning to Detect Alzheimer's Disease from Circulating Non-coding RNAs |
| Q89484972 | Metabolic Profiles Help Discriminate Mild Cognitive Impairment from Dementia Stage in Alzheimer's Disease |
| Q38877855 | Metabolic network failures in Alzheimer's disease: A biochemical road map. |
| Q41690749 | Metabolic status of CSF distinguishes rats with tauopathy from controls. |
| Q41196957 | Metabolomics and cognition in African American adults in midlife: the atherosclerosis risk in communities study |
| Q64119123 | Metabolomics in the Development and Progression of Dementia: A Systematic Review |
| Q90452789 | Perspective: The Potential Role of Circulating Lysophosphatidylcholine in Neuroprotection against Alzheimer Disease |
| Q89945308 | Perspectives in fluid biomarkers in neurodegeneration from the 2019 biomarkers in neurodegenerative diseases course-a joint PhD student course at University College London and University of Gothenburg |
| Q93117067 | Primary fatty amides are potential plasma biomarkers for AD |
| Q91947146 | Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort |
| Q37543795 | Prospective associations of plasma phospholipids and mild cognitive impairment/dementia among African Americans in the ARIC Neurocognitive Study |
| Q33801596 | Serum Amino Acid Profiles in Normal Subjects and in Patients with or at Risk of Alzheimer Dementia |
| Q47165587 | Serum neurofilament light in familial Alzheimer disease: A marker of early neurodegeneration |
| Q90089057 | Sets of coregulated serum lipids are associated with Alzheimer's disease pathophysiology |
| Q89983254 | Sex and APOE ε4 genotype modify the Alzheimer's disease serum metabolome |
| Q59811719 | Systematic Analysis and Biomarker Study for Alzheimer's Disease |
| Q42379364 | Targeted metabolomics and medication classification data from participants in the ADNI1 cohort |
| Q48762558 | Understanding mechanisms and seeking cures for Alzheimer's disease: why we must be "extraordinarily diverse". |
Search more.